The test simultaneously amplifies and detects two separate regions of the HIV-1 genome, which are not subject to selective drug pressure. This unique, dual-target design allows for more reliable results to confidently and effectively diagnose HIV-1 infection.
Roche representatives said the new dual-target HIV-1 qualitative test, v2.0, works with plasma and dried-blood spot collection cards to facilitate testing, and more importantly makes sample collection and transportation easy, even from the smallest infant in the most rural area.
The new test will help increase access for early infant HIV diagnosis, the company said.
The collection card and the need for more sensitive and accurate information to diagnose babies early in their life and patients across many African countries is instrumental to facilitate the state-of-the-art healthcare required for the region. The HIV-1 dual-target qualitative test and sample cards eliminate need for refrigeration while also reducing the volume of blood to be stored or transported and improving stress levels for the mother and child.
"The ability to determine the HIV status of an infant as early as six weeks is crucial to determining the appropriate care and support for HIV-positive babies," stated Paul Brown, president of Roche Molecular Diagnostics. "With this new solution from Roche, we are reiterating our commitment to healthcare solutions that make a real difference for patients."
Headquartered in Basel, Switzerland, Roche's Pleasanton-based Molecular Diagnostics facilities are located in Hacienda Business Park at 4300 Hacienda Dr.